75 related articles for article (PubMed ID: 20414126)
1. Risedronate-induced arthritis.
Yemisci OU; Yalbuzdag SA; Karatas M
J Clin Rheumatol; 2010 Jun; 16(4):168-9. PubMed ID: 20414126
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.
Ilter E; Karalok H; Tufekci EC; Batur O
Climacteric; 2006 Apr; 9(2):129-34. PubMed ID: 16698659
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate-associated arthritis.
Diaz-Borjon A; Seyler TM; Chen NL; Lim SS
J Clin Rheumatol; 2006 Jun; 12(3):131-3. PubMed ID: 16755241
[TBL] [Abstract][Full Text] [Related]
5. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907
[TBL] [Abstract][Full Text] [Related]
6. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
7. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.
Bock O; Boerst H; Thomasius FE; Degner C; Stephan-Oelkers M; Valentine SM; Felsenberg D
J Musculoskelet Neuronal Interact; 2007; 7(2):144-8. PubMed ID: 17627083
[TBL] [Abstract][Full Text] [Related]
8. Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.
Racewicz AJ; Schofield PJ; Cahall DL; Cline GA; Burgio DE
Curr Med Res Opin; 2007 Dec; 23(12):3079-89. PubMed ID: 17971285
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
[TBL] [Abstract][Full Text] [Related]
10. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Delmas PD; McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S
Bone; 2008 Jan; 42(1):36-42. PubMed ID: 17920005
[TBL] [Abstract][Full Text] [Related]
12. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
13. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
14. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
15. Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases.
Brooks JK; Gilson AJ; Sindler AJ; Ashman SG; Schwartz KG; Nikitakis NG
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jun; 103(6):780-6. PubMed ID: 17223592
[TBL] [Abstract][Full Text] [Related]
16. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
Bahlous A; Bouzid K; Sahli H; Sallami S; Abdelmoula J
Tunis Med; 2009 Jun; 87(6):380-1. PubMed ID: 19927782
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Brown JP; Kendler DL; McClung MR; Emkey RD; Adachi JD; Bolognese MA; Li Z; Balske A; Lindsay R
Calcif Tissue Int; 2002 Aug; 71(2):103-11. PubMed ID: 12085156
[TBL] [Abstract][Full Text] [Related]
18. Periodontal assessment of postmenopausal women receiving risedronate.
Palomo L; Bissada NF; Liu J
Menopause; 2005; 12(6):685-90. PubMed ID: 16278611
[TBL] [Abstract][Full Text] [Related]
19. Osteochemonecrosis of jaws and bisphosphonates.
Khosa AD; Nayyar MS; Beirne JC
Ir Med J; 2007 Mar; 100(3):410-1. PubMed ID: 17491545
[TBL] [Abstract][Full Text] [Related]
20. The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
Yanik B; Bavbek N; Yanik T; Inegöl I; Kanbay M; Turgut FH; Uz E; Akçay A
Ren Fail; 2007; 29(4):471-6. PubMed ID: 17497471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
